Distribution of estrogen and progesterone receptors isoforms in endometrial cancer

Diagnostic Pathology

Eliezer Shalev¹  Irit Elmalah²  Shlomit Goldman³  Jana Pricop²  Hila Kreizman-Shefer² 

[1] Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel;Emek Cancer Diagnosis and Research Institute (ECDRI), Emek Medical Center, Afula, Israel;Laboratory for Research in Reproductive Sciences and Department of Obstetrics and Gynecology, Emek Medical Center, Afula, Israel

关键词: Progesterone receptor;    Estrogen receptor;    Endometrial carcinoma;   

Others  :  801996
DOI  :  10.1186/1746-1596-9-77

 received in 2014-01-20, accepted in 2014-02-25,  发布年份 2014

【 摘 要 】

Background

70–80% of sporadic endometrial carcinomas are defined as endometrioid carcinoma (EC). Early-stage, well differentiated endometrial carcinomas usually retain expression of estrogen and progesterone receptors (ER and PR, respectively), as advanced stage, poorly differentiated tumors often lack one or both of these receptors. Well-described EC prognosis includes tumor characteristics, such as depth of myometrial invasion. Therefore, in the current study, we evaluated the expression profile of ER and PR isoforms, including ER-α, PR-A and PR–B, in correlation to EC tumor histological depth.

Methods

Using immunohistochemistry and image analysis software, the expression of ER-α, PR-A, PR–B and Ki67 was assessed in endometrial stroma and epithelial glands of superficial, deep and extra-tumoral sections of 15 paraffin embedded EC specimens, and compared to 5 biopsies of non-malignant endometrium.

Results

Expression of PR-A and ER-α was found to be lower in EC compared to nonmalignant tissue, as the stromal expression was dramatically reduced compared to epithelial cells. Expression ratios of both receptors were significantly high in superficial and deep portions of EC; in non-tumoral portion of EC were close to the ratios of nonmalignant endometrium. PR-B expression was low in epithelial glands of EC superficial and deep portions, and high in the extra-tumoral region. Elevated PR-B expression was found in stroma of EC, as well.

Conclusions

The ratio of ER-α and PR-A expression in the epithelial glands and the stroma of EC biopsies may serve as an additional parameter in the histological evaluation of EC tumor.

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1155060506119016 webcite

【 授权许可】

   
2014 Kreizman-Shefer et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Baylin SB, Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000, 16(4):168-174.
• [2]Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D: Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995, 85:304-313.
• [3]Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983, 15:7-10.
• [4]Pertschuk LP, Masood S, Simone J, Feldman JG, Fruchter RG, Axiotis CA, Greene GZ: Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol 1996, 63:28-33.
• [5]Gehrig PA, Van Le L, Olatidoye B, Geradts J: Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer (Phila.) 1999, 86:2083-2089.
• [6]Ito K, Utsunomiya H, Yaegashi N, Sasano H: Biological roles of estrogen and progesterone in human endometrial carcinoma – new developments in potential endocrine therapy for endometrial cancer. Endocr J 2007, 54(5):667-679.
• [7]Klinge CM: Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001, 29:2905-2919.
• [8]Mueller SO, Korach KS: Estrogen receptors and endocrine diseases: lessons from estrogen receptor knockout mice. Curr Opin Pharmacol 2001, 1:613-619.
• [9]Yang P, Kriatchko A, Roy SK: Expression of ER-alpha and ER-beta in the hamster ovary: differential regulation by gonadotropins and ovarian steroid hormones. Endocrinology 2002, 143:2385-2398.
• [10]Förster C, Mäkela S, Wärri A, Kietz S, Becker D, Hultenby K, Warner M, Gustafsson JA: Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci USA 2002, 99:15578-15583.
• [11]Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P: Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990, 9(5):1603-1614.
• [12]Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP: The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol 2000, 20(9):3102-3115.
• [13]Horwitz K: The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev 1992, 13(2):146-163.
• [14]Clarke CL, Sutherland RL: Progestin regulation of cellular proliferation. Endocr Rev 1990, 11:266-302.
• [15]Graham JD, Clarke CL: Physiological action of progesterone in target tissues. Endocr Rev 1997, 18:502-519.
• [16]Soper JT, McCarty KS Jr, Creasman WT, Clarke-Pearson DL, McCarty KS Sr: Induction of cytoplasmic progesterone receptor in human endometrial carcinoma transplanted into nude mice. Am J Obstet Gyneco 1984, 150(4):437-439.
• [17]Arnett-Mansfield RL, de Fazio A, Wain GV, Jaworski RC, Byth K, Mote PA, Clarke CL: Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 2001, 61:4576-4582.
• [18]Jazaeri AA, Nunes KJ, Dalton MS, Xu M, Shupnik MA, Rice LW: Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene 2001, 20:6965-6969.
• [19]Farr CJ, Easty DJ, Ragoussis J, Collignon J, Lovell-Badge R, Goodfellow PN: Characterization and mapping of the human SOX4 gene. Mamm Genome 1993, 4(10):577-584.
• [20]Fujimoto J, Ichigo S, Hirose R, Sakaguchi H, Tamaya T: Clinical implication of expression of progesterone receptor form A and B mRNAs in secondary spreading of gynecologic cancers. J Steroid Biochem Mol Biol 1997, 62(5–6):449-454.
• [21]Scholzen T, Gerdes J: The Ki-67 protein: From the known and the unknown. J Cell Physiol 2000, 182(3):311-322.
• [22]Oreskovic S, Babic D, Kalafatic D, Barisic D, Beketic-Oreskovic L: A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol 2004, 93:34-40.
• [23]Nielsen AL, Nyholm HC: Proliferative activity as revealed by Ki-67 in uterine adenocarcinoma of endometrioid type: comparison of tumours from patients with and without previous oestrogen therapy. J Pathol 1993, 171(3):199-205.
• [24]Stefansson IM, Salvesen HB, Immervoll H, Akslen LA: Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology 2004, 44:472-479.
• [25]Cheung ANY, Chiu PM, Tsun KL, Khoo US, Leung BSY, Ngan HYS: Chromosome in situ hybridisation, Ki-67, and telomerase immunocytochemistry in liquid based cervical cytology. J Clin Pathol 2004, 57(7):721-727.
• [26]Carcangiu ML, Chambers JT, Voynick IM, Pirro M, Schwartz PE: Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: clinical and histologic correlations. Am J Clin Pathol 1990, 94:247-254.
• [27]Singh M, Zaino RJ, Filiaci VJ, Leslie KK: Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2007, 106(2):325-333.
• [28]Lim CS, Baumann CT, Htun H, Xian W, Irie M, Smith CL, Hager GL: Differential localization and activity of the A and B-forms of the human progesterone receptor using green fluorescent protein chimeras. Mol Endocrinol 1999, 13:366-375.
• [29]Leslie KK, Stein MP, Kumar NS, Dai D, Stephens J, Wandinger-Ness A, Glueck DH: Progesterone receptor isoform identification and subcellular localization in endometrial cancer. Gynecol Oncol 2005, 96:32-41.
• [30]Kerner H, Sabo E, Friedman M, Beck D, Samare O, Lichtig C: An immunohistochemical study of estrogen and progesterone receptors in adenocarcinoma of the endometrium and in the adjacent mucosa. Int J Gynecol Cancer 1995, 5(4):275-281.
• [31]Markman M: Hormonal therapy of endometrial cancer. Eur J Cancer 2005, 41(5):673-675.
• [32]Kato H, Kato S, Kumabe T, Sonoda Y, Yoshimoto T, Kato S, Han SY, Suzuki T, Shibata H, Kanamaru R, Ishioka C: Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 2000, 6:3937-3943.
• [33]Fujimoto J, Sakaguchi H, Aoki I, Khatun S, Toyoki H, Tamaya T: Steroid receptors and metastatic potential in endometrial cancers. J Steroid Biochem Mol Biol 2000, 75:209-212.
• [34]Smuc T, Laniˇsnik Riˇzner T: Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Mol Cell Endocrinol 2009, 301:74-82.
• [35]Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW: Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 2000, 13(4):379-388.
• [36]Maeda K, Tsuda H, Hashiguchi Y, Yamamoto K, Inoue T, Ishiko O, Ogita S: Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer. Hum Pathol 2000, 33(4):386-391.
• [37]Collins F, MacPherson S, Brown P, Bombail V, Williams ARW, Anderson RA, Jabbour HN, Saunders PTK: Expression of oestrogen receptors, ERα, ERβ, and ERβ variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERα. BMC Cancer 2009, 9:330.
• [38]Gul AE, Keser SH, Barisik NO, Kandemir NO, Cakır C, Sensu S, Karadayi N: The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas. Diagn Pathol 2010, 5:13. BioMed Central Full Text
• [39]Barrena Medel NI, Bansal S, Miller DS, Wright JD, Herzog TJ: Pharmacotherapy of endometrial cancer. Expert Opin Pharmaco 2009, 10(12):1939-1951.
• [40]Issa JP, Zehnbauer BA, Civin CI, Collector MI, Sharkis SJ, Davidson NE, Kaufmann SH, Baylin SB: The estrogen receptor CpG Island is methylated in most hematopoietic neoplasms. Cancer Res 1996, 56:973-977.
• [41]Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA, Baylin SB, Issa JP, Davidson NE: Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 1996, 2:805-810.
• [42]Issa JP, Baylin SB, Belinsky SA: Methylation of the estrogen receptor CpG Island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res 1996, 56:3655-3658.
• [43]Li Q, Jedlicka A, Ahuja N, Gibbons MC, Baylin SB, Burger PC, Issa JP: Concordant methylation of the ER and N33 genes in glioblastoma multiforme. Oncogene 1998, 16:3197-3202.
• [44]Couse JF, Korach KS: Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 1999, 20:358-417.
• [45]Dvorakova E, Chmelarova M, Laco J, Palicka V, Spacek J: Methylation analysis of tumor suppressor genes in endometroid carcinoma of endometrium using MS-MLPA. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013, 157(4):298-303.
• [46]Fujimoto J, Ichigo S, Hori M, Nishigaki M, Tamaya T: Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors. Tumour Biol 1995, 16:254-260.
• [47]Saito T, Mizumoto H, Tanaka R, Satohisa S, Adachi K, Horie M, Kudo R: Overexpressed progesterone receptor form B inhibits invasive activity suppressing matrix metalloproteinases in endometrial carcinoma cells. Cancer Lett 2004, 209:237-243.
• [48]Miyamoto T, Watanabe J, Hata H, Jobo T, Kawaguchi M, Hattori M, Saito M, Kuramoto H: Significance of progesterone receptor-A and -B expressions in endometrial adenocarcinoma. J Steroid Biochem Mol Biol 2004, 92:111-118.
• [49]Jongen V, Briët J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H, Hollema H: Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 2009, 112(3):537-542.
• [50]Tornos C, Silva EG, El-Naggar A, Burke TW: Aggressive stage I grade 1 endometrial carcinoma. Cancer 1992, 70(4):790-798.
• [51]Fukuda K, Mori M, Uchiyama M, Iwai K, Iwasaka T, Sugimori H: Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol 1998, 69:220-225.
• [52]Savouret JF, Rauch M, Redeuilh G, Sar S, Chauchereau A, Woodruff K, Parker MG, Milgrom E: Interplay between estrogens, progestins, retinoic acid and AP-1. J Biol Chem 1994, 269:28955-28962.
• [53]Lesniewicz T, Kanczuga-Koda L, Baltaziak M, Jarzabek K, Rutkowski R, Koda M, Wincewicz A, Sulkowska M, Sulkowski S: Comparative evaluation of estrogen and progesterone receptor expression with connexins 26 and 43 in endometrial cancer. Int J Gynecol Cancer 2009, 19(7):1253-1257.
• [54]Cooke PS, Buchanan DL, Young P, Setiawan T, Brody J, Korach KS, Taylor J, Lubahn DB, Cunha GR: Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc Natl Acad Sci USA 1997, 94:6535-6540.
• [55]Inaba T, Wiest WG, Strickler RC, Mori J: Augmentation of the response of mouse uterine epithelial cells to estradiol by uterine stroma. Endocrinology 1988, 123:1253-1258.
• [56]Kurita T, Young P, Brody JR, Lydon JP, O’Malley BW, Cunha GR: Stromal progesterone receptors mediate the inhibitory effects of progesterone on estrogen-induced uterine epithelial cell deoxyribonucleic acid synthesis. Endocrinology 1998, 139(11):4708-4713.
• [57]Beavon IR: The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer 2000, 36:1607-1620.
• [58]Hanekamp EE, Gielen SCJP, Smid-Koopman E, Kuhne LCM, de Ruiter PE, Chadha-Ajwani S, Brinkmann AO, Grootegoed JA, Burger CW, Huikeshoven FJ, Blok LJ: Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin Cancer Res 2003, 9(11):4190-4199.
• [59]Montserrat N, Mozos A, Llobet D, Dolcet X, Pons C, de Herreros AG, Matias-Guiu X, Prat J: Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma. Hum Pathol 2012, 43:632-643.
• [60]Llaurado M, Ruiz A, Majem B, Ertekin T, Colás E, Pedrola N, Devis L, Rigau M, Sequeiros T, Montes M, Garcia M, Cabrera S, Gil-Moreno A, Xercavins J, Castellví J, Garcia A, Ramón y Cajal S, Moreno G, Alameda F, Vázquez-Levin M, Palacios J, Prat J, Doll A, Matías-Guiu X, Abal M, Reventós J: Molecular bases of endometrial cancer: new roles for new actors in the diagnosis and the therapy of the disease. Mol Cell Endocrinol 2012, 358:244-255.
• [61]Wik E, Ræder MB, Krakstad C, Trovik J, Birkeland E, Hoivik EA, Mjos S, Werner HMJ, Mannelqvist M, Stefansson IM, Oyan AM, Kalland KH, Akslen LA, Salvesen HB: Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin Cancer Res 2013, 19(5):1094-1105.
• [62]Sasaki M, Kaneuchi M, Fujimoto S, Tanaka Y, Dahiya R: Hypermethylation can selectively silence multiple promoters of steroid receptors in cancers. Mol Cell Endocrinol 2003, 202(1–2):201-207.
• [63]Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, Jeschke U, Friese K, Mylonas I: Prognostic significance of oestrogen receptor alpha (ERα) and beta (ERβ), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 2007, 43(16):2434-2444.
• [64]Balmer NN, Richer JK, Spoelstra NS, Torkko KC, Lyle PL, Singh M: Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: correlation with clinicopathologic parameters and biomarkers. Mod Pathol 2006, 19(12):1593-1605.
• [65]Zafran N, Levin A, Goldman S, Shalev E: Progesterone receptor’s profile and the effect of the hormone and its derivatives on invasiveness and MMP2 secretion in endometrial carcinoma cell lines. Harefuah 2009, 148(7):416-419. 477. Hebrew
• [66]Vegeto E, Shahbaz MM: Human progesterone receptor A form is a cell and promoter specific repressor of human progesterone receptor B function. Mol Endocrinol 1993, 7:1244-1255.
• [67]Khan JA, Amazit L, Bellance C, Guiochon-Mantel A, Lombès M, Loosfelt H: p38 and p42/44 MAPKs differentially regulate progesterone receptor A and B isoform stabilization. Mol Endocrinol 2011, 25(10):1710-1724.
• [68]Ryan AJ, Susil B, Jobling TW, Oehler MK: Endometrial cancer. Cell Tissue Res 2005, 322:53-61.
• [69]Apostolou G, Apostolou N, Biteli M, Kavantzas N, Patsouris E, Athanassiadou P: Utility of Ki-67, p53, Bcl-2, and Cox-2 biomarkers for low-grade endometrial cancer and disordered proliferative/benign hyperplastic endometrium by imprint cytology. Diagn Cytopathol 2013. doi:10.1002/dc.23010. [Epub ahead of print]
• [70]Han G, Sidhu D, Duggan MA, Arseneau J, Cesari M, Clement PB, Ewanowich CA, Kalloger SE, Köbel M: Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod Pathol 2013, 26:1594-1604.
• [71]Canlorbe G, Laas E, Bendifallah S, Daraï E, Ballester M: Contribution of immunohistochemical profile in assessing histological grade of endometrial cancer. Anticancer Res 2013, 33(5):2191-2198.
• [72]Buell-Gutbrod R, Sung CJ, Lawrence WD, Quddus MR: Endometrioid adenocarcinoma with simultaneous endocervical and differentiation: report of a rare phenomenon and the immunohistochemical profile. Diagn Pathol 2013, 8:128. BioMed Central Full Text
• [73]Gun BD, Bahadir B, Bektas S, Barut F, Yurdakan G, Kandemir NO, Ozdamar SO: Clinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma. Diagn Pathol 2012, 7:80. BioMed Central Full Text
• [74]Liang S, Mu K, Wang Y, Zhou Z, Zhang J, Sheng Y, Zhang T: CyclinD1, a prominent prognostic marker for endometrial diseases. Diagn Pathol 2013, 8:138. BioMed Central Full Text